Wild-type minimum effective concentration distributions and epidemiologic cutoff values for caspofungin and Aspergillus spp. as determined by Clinical and Laboratory Standards Institute broth microdilution methods
- PMID: 20207095
- DOI: 10.1016/j.diagmicrobio.2010.01.001
Wild-type minimum effective concentration distributions and epidemiologic cutoff values for caspofungin and Aspergillus spp. as determined by Clinical and Laboratory Standards Institute broth microdilution methods
Abstract
Antifungal susceptibility testing of Aspergillus spp. against caspofungin has been standardized by the Clinical and Laboratory Standards Institute (CLSI). Recent studies have documented breakthrough infections with Aspergillus spp. for which the minimum effective concentration (MEC) for caspofungin ranged from 0.25 to 8 microg/mL. We tested a collection of 1590 clinical isolates of Aspergillus spp. (188 Aspergillus flavus, 1187 Aspergillus fumigatus, 114 Aspergillus niger, 71 Aspergillus terreus, and 30 Aspergillus versicolor) against caspofungin using the CLSI broth microdilution method. An epidemiologic cutoff value (ECV) of <or=0.06 microg/mL encompassed the wild-type (WT) MEC distribution (percentage of MECs) of A. flavus (99.5%), A. fumigatus (98.7%), A. niger (100%), and A. terreus (97.2%), and an ECV of <or=0.12 microg/mL encompassed the WT distribution of A. versicolor (96.7%). A total of 20 strains showed MECs that were outside the ECVs: 1 A. flavus (0.12 microg/mL), 16 A. fumigatus (0.12 microg/mL [13], 1 microg/mL [1], 2 microg/mL [2]), 2 A. terreus (0.12 [1] and >8 microg/mL [1]), and 1 A. versicolor (4 microg/mL). The establishment of the WT MEC distributions and ECVs for caspofungin and the major species of Aspergillus will be useful in resistance surveillance and is an important step toward the development of clinical breakpoints.
(c) 2010 Elsevier Inc. All rights reserved.
Similar articles
-
Wild-type MIC distributions and epidemiological cutoff values for caspofungin and Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document).Antimicrob Agents Chemother. 2011 Jun;55(6):2855-9. doi: 10.1128/AAC.01730-10. Epub 2011 Mar 21. Antimicrob Agents Chemother. 2011. PMID: 21422219 Free PMC article.
-
In vitro susceptibility of clinical isolates of Aspergillus spp. to anidulafungin, caspofungin, and micafungin: a head-to-head comparison using the CLSI M38-A2 broth microdilution method.J Clin Microbiol. 2009 Oct;47(10):3323-5. doi: 10.1128/JCM.01155-09. Epub 2009 Aug 26. J Clin Microbiol. 2009. PMID: 19710267 Free PMC article.
-
[Comparison of minimum inhibitory and minimum effective concentration values for the detection of in vitro susceptibilities of Aspergillus species against caspofungin].Mikrobiyol Bul. 2007 Apr;41(2):285-90. Mikrobiyol Bul. 2007. PMID: 17682716 Turkish.
-
Candida and candidaemia. Susceptibility and epidemiology.Dan Med J. 2013 Nov;60(11):B4698. Dan Med J. 2013. PMID: 24192246 Review.
-
In vitro susceptibility testing in Aspergillus species: an update.Future Microbiol. 2010 May;5(5):789-99. doi: 10.2217/fmb.10.34. Future Microbiol. 2010. PMID: 20441550 Review.
Cited by
-
Invasive Aspergillosis by Aspergillus flavus: Epidemiology, Diagnosis, Antifungal Resistance, and Management.J Fungi (Basel). 2019 Jul 1;5(3):55. doi: 10.3390/jof5030055. J Fungi (Basel). 2019. PMID: 31266196 Free PMC article. Review.
-
The pharmacokinetic-pharmacodynamic modeling and cut-off values of tildipirosin against Haemophilus parasuis.Oncotarget. 2017 Dec 7;9(2):1673-1690. doi: 10.18632/oncotarget.23018. eCollection 2018 Jan 5. Oncotarget. 2017. PMID: 29416722 Free PMC article.
-
Antifungal susceptibilities of Aspergillus fumigatus clinical isolates obtained in Nagasaki, Japan.Antimicrob Agents Chemother. 2012 Jan;56(1):584-7. doi: 10.1128/AAC.05394-11. Epub 2011 Oct 24. Antimicrob Agents Chemother. 2012. PMID: 22024829 Free PMC article.
-
Use of matrix-assisted laser desorption ionization-time of flight mass spectrometry for caspofungin susceptibility testing of Candida and Aspergillus species.J Clin Microbiol. 2012 Jul;50(7):2479-83. doi: 10.1128/JCM.00224-12. Epub 2012 Apr 25. J Clin Microbiol. 2012. PMID: 22535984 Free PMC article.
-
Optimal Regimens and Clinical Breakpoint of Avilamycin Against Clostridium perfringens in Swine Based on PK-PD Study.Front Pharmacol. 2022 Feb 24;13:769539. doi: 10.3389/fphar.2022.769539. eCollection 2022. Front Pharmacol. 2022. PMID: 35281904 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous